Tandem Diabetes Care, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John F. Sheridan
- Full Time Employees
- 2,500
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 12400 High Bluff Drive San Diego CA United States 92130
- IPO Date
- Nov 14, 2013
- CIK
- 0001438133
- Website
- tandemdiabetes.com
- Similar Companies
- Business
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) designs, develops, manufactures and commercializes advanced automated insulin delivery systems and related products for people with insulin-dependent diabetes, including type 1 and type 2 diabetes; its core offerings include the t:slim X2 insulin pump with integrated color touchscreen and Control-IQ+ advanced hybrid closed-loop technology featuring predictive algorithms with AutoBolus capability for ages 2+ (type 1) and 18+ (type 2), the Tandem Mobi system as a compact tubeless insulin pump with smartphone control (iOS), 200-unit insulin capacity, Dexcom G6/G7 continuous glucose monitoring compatibility and inductive wireless charging, infusion sets with varied cannula materials, tubing lengths and insertion angles, t:connect diabetes management software for data visualization and remote software updates, and innovative mobile/cloud-based applications for therapy monitoring; the company also provides 24/7 support, expert training and limited warranties. Founded in 2006 and headquartered in San Diego, California, Tandem operates globally with sales in the United States and international markets, targeting people with diabetes, healthcare providers and distribution channels including durable medical equipment and pharmacy rebates covering approximately 20% of U.S. lives; it maintains partnerships with Dexcom for CGM integration, Abbott, Unomedical (Convatec) for infusion sets and the University of Virginia Center for Diabetes Technology for fully automated closed-loop research. Recent developments include U.S. FDA clearance for Control-IQ+ expansion to type 2 diabetes patients, successful 2024 U.S. launch of Tandem Mobi via multi-channel strategy with quarter-over-quarter shipment growth, completion of the 2024 Tandem Choice program, return to positive free cash flow, maintenance of full-year revenue guidance at $1 billion with double-digit growth focus, international shift to direct sales for higher average selling prices, sales force expansion, planned 2026 commercial launch of tubeless Mobi to capture type 2 market share, and 2023 acquisition of AMF Medical SA to integrate the Sigi rechargeable patch pump technology into its portfolio.
Company News
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
Does TNDM Stock Still Deserve a Place in Your Portfolio?
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026